论文部分内容阅读
目的探讨应用唑来膦酸治疗绝经后骨质疏松症(OP)的疗效及患者依从性。方法选取2015年6月-2016年5月天津市职业病防治院骨科就诊的139例绝经后女性OP患者,通过随机数字表法分为观察组70例种对照组69例,观察组应用唑来膦酸联合口服骨化三醇及钙剂治疗,对照组给予口服骨化三醇和钙剂治疗。对比治疗前后两组腰椎(L1-L4)、股骨颈、Wards区、髋部总量骨密度以及疼痛VAS评分。结果接受治疗1年后,观察组及对照组患者骨密度较治疗前均明显提高,观察组患者VAS疼痛评分明显低于对照组,差异均有统计学意义(P<0.05)。观察组约50%的患者发生了轻到中度的不良反应,无严重不良反应发生,大多数患者同意继续使用该药。结论使用唑来膦酸预防和治疗绝经后OP,疗效确切,安全性高,依从性好,值得临床推广应用。
Objective To investigate the efficacy and compliance of zoledronic acid in the treatment of postmenopausal osteoporosis (OP). METHODS: One hundred and ninety-nine postmenopausal women with osteoporosis undergoing orthopedics in Tianjin Occupational Disease Prevention and Treatment Hospital from June 2015 to May 2016 were selected and divided into observation group (70 cases) and control group (69 cases) by random number table. The observation group was treated with zoledronic acid Acid combined oral calcitriol and calcium treatment, the control group was given oral calcitriol and calcium treatment. The lumbar spine (L1-L4), femoral neck, Wards area, total hip density and VAS scores were compared before and after treatment. Results After 1 year of treatment, the bone mineral density in observation group and control group were significantly higher than those before treatment, and VAS pain score in observation group was significantly lower than that in control group (P <0.05). About 50% of patients in the observation group had mild to moderate adverse reactions, and no serious adverse reactions occurred. Most patients agreed to continue using the drug. Conclusion The use of zoledronic acid in the prevention and treatment of postmenopausal OP, the exact effect, high safety, good compliance, is worthy of clinical application.